{"news_desk": "OpEd", "print_page": "35", "section_name": "Opinion", "subsection_name": null, "byline": {"original": "By NICHOLAS KRISTOF", "person": [{"rank": 1, "role": "reported", "firstname": "Nicholas", "organization": "", "lastname": "KRISTOF"}]}, "abstract": "Nicholas Kristof Op-Ed column claims Johnson & Johnson deliberately and unethically marketed antipsychotic drug too broadly to maximize profits, which reached almost $30 billion globally, while paying just over $2 billion in settlements with consumers suffering deleterious side effects; episode is recounted in new book by journalist Steven Brill.  ", "type_of_material": "Op-Ed", "word_count": "803", "lead_paragraph": "Marketing the antipsychotic got Johnson & Johnson a criminal record, big settlement costs and penalties \u2014 and bigger profits.", "pub_date": "2015-09-17T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "When Crime Pays: J&amp;J\u2019s Drug Risperdal", "content_kicker": "Op-Ed Columnist", "print_headline": "Drug Crime That Paid Billions  ", "kicker": "Op-Ed Columnist"}, "snippet": "Marketing the antipsychotic got Johnson & Johnson a criminal record, big settlement costs and penalties \u2014 and bigger profits.", "multimedia": [{"height": 126, "url": "images/2015/09/17/opinion/17kristof/17kristof-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/09/17/opinion/17kristof/17kristof-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 400, "url": "images/2015/09/17/opinion/17kristof/17kristof-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "400", "xlarge": "images/2015/09/17/opinion/17kristof/17kristof-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/09/17/opinion/17kristof/17kristof-thumbStandard-v2.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/09/17/opinion/17kristof/17kristof-thumbStandard-v2.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/09/17/opinion/nicholas-kristof-when-crime-pays-jjs-drug-risperdal.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Johnson & Johnson", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Advertising and Marketing", "name": "subject"}, {"rank": "4", "is_major": "Y", "value": "Brill, Steven", "name": "persons"}, {"rank": "5", "is_major": "N", "value": "Gorsky, Alex", "name": "persons"}, {"rank": "6", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Omnicare Inc", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "Ethics and Official Misconduct", "name": "subject"}, {"rank": "9", "is_major": "N", "value": "Elderly", "name": "subject"}], "blog": [], "_id": "55fa69f138f0d816d18468a0", "source": "The New York Times"}